Shares of agilon health, inc. (AGL) plummeted 28.93% in Tuesday's trading session following a series of disappointing announcements from the company. The healthcare platform provider reported weak second-quarter results, announced a leadership transition, and withdrew its full-year 2025 guidance, leaving investors concerned about the company's near-term prospects.

Agilon Health's Q2 2025 financial results fell short of expectations across the board. The company reported revenue of $1.39 billion, a 6% decrease year-over-year and below the analyst consensus estimate of $1.47 billion. The net loss widened to $104 million, compared to a $31 million loss in the same quarter last year. Adjusted EBITDA came in at a loss of $83 million, significantly worse than the estimated loss of $28.4 million.

Adding to investor concerns, Agilon Health announced that CEO Steven Sell has stepped down from his roles as President, CEO, and Board Director. Ronald A. Williams, a co-founder and current Board Chairman, has been appointed Executive Chairman to lead an interim Office of the Chairman while a search for a permanent CEO is conducted. Furthermore, the company withdrew its full-year 2025 financial guidance, citing ongoing performance visibility initiatives and dynamic market conditions. These developments have created uncertainty around Agilon Health's future performance and strategy, contributing to the sharp decline in its stock price.